Cipher Pharmaceuticals (TSE:CPH) Hits New 1-Year High at $13.25

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as C$13.25 and last traded at C$12.80, with a volume of 97659 shares traded. The stock had previously closed at C$12.13.

Wall Street Analysts Forecast Growth

Separately, Stifel Nicolaus lowered shares of Cipher Pharmaceuticals from a “buy” rating to a “hold” rating and upped their price objective for the company from C$8.00 to C$9.50 in a research note on Monday, May 13th.

Cipher Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.38, a current ratio of 7.96 and a quick ratio of 2.67. The company has a fifty day moving average of C$8.89 and a 200-day moving average of C$8.22. The firm has a market cap of C$298.96 million, a P/E ratio of 10.08 and a beta of 1.05.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last posted its earnings results on Thursday, May 9th. The company reported C$0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of C$0.14 by C$0.13. Cipher Pharmaceuticals had a net margin of 102.43% and a return on equity of 29.70%. The firm had revenue of C$7.91 million during the quarter, compared to analyst estimates of C$7.04 million. On average, sell-side analysts anticipate that Cipher Pharmaceuticals Inc. will post 0.74 EPS for the current fiscal year.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.